<DOC>
	<DOCNO>NCT03064438</DOCNO>
	<brief_summary>The study evaluate safety , efficacy tolerability ACCU-D1 apply twice daily 12 week adult patient moderate severe acne rosacea . Two third participant receive ACCU-D1 one third receive vehicle control .</brief_summary>
	<brief_title>Efficacy Accu-D1 Treatment Acne Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Patient male nonpregnant female least 18 year age Patient ten forty inflammatory lesion rosacea face Randomization Clinical diagnosis mild severe facial rosacea determine Investigator 's Global Assessment ( IGA ) Randomization A score great moderate Clinical Erythema Assessment Scale Informed consent obtain subject copy sign consent provide subject Patient pregnant planning become pregnant Patient take topical oral therapy may affect patient 's rosacea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>